Head-to-head evidence
IBI3016 vs ION904
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensinogen (AGT) · full Hypertension pipeline
IBI3016
Developed by Suzhou Sanegene Bio and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07838220 (registry estimate)
ION904
Developed by Ionis Pharmaceuticals
NCT05314439 · Phase 2 · completed
The study randomly assigned 48 participants to ION904 or placebo and masked participants, investigators, and outcome assessors. However, its primary endpoint was the surrogate biomarker plasma angiotensinogen, and no primary endpoint results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IBI3016's landscape · ION904's landscape